Format

Send to

Choose Destination
See comment in PubMed Commons below
Invest New Drugs. 1990 Nov;8(4):397-9.

Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.

Author information

  • 1University of Wisconsin Clinical Cancer Center, Madison 53792.

Abstract

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.

PMID:
2084074
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center